FDA Accepts Supplement Application for Ibuprofen and Famotidine by Alkem Labs
The FDA has accepted a supplemental application for a combination product of ibuprofen and famotidine submitted by Alkem Labs.
Asset / Drug
Drug and asset intelligence for Ibuprofen with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Combination Therapy
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.